Plasma C-terminal cross-linking telopeptide of type II collagen as a biomarker in advanced stages of femoral head osteonecrosis - 16/02/19
pages | 8 |
Iconographies | 8 |
Vidéos | 0 |
Autres | 0 |
Graphical abstract |
Patients diagnosed with FHN and age- and sex-matched healthy subjects were included in this cross-sectional case-control study between May 2016 and November 2016. Venous blood samples were collected for Enzyme-linked immunosorbent assay to determine the protein levels of CTX-II. Bone histomorphology, cartilaginous immunohistochemistry, and Western blotting, as well as the receiver operating characteristic (ROC) curve, were evaluated.
Highlights |
• | This is the first article to investigate the relationship between CTX Ⅱ level and the FHN both in plasma and tissue level. |
• | This article has a large number of patients included and results can unmask the potential use of CTX Ⅱ in FHN. |
• | Post hoc statistical power calculation and ROC curve were performed and revealed the sample scale was reliable. |
• | We found the correlation between the plasma level of CTX Ⅱ and the progression of the disease.This is the first article to investigate the relationship between CTX Ⅱ level and the FHN both in plasma and tissue level. |
• | This article has a large number of patients included and results can unmask the potential use of CTX Ⅱ in FHN. |
• | Post hoc statistical power calculation and ROC curve were performed and revealed the sample scale was reliable. |
• | We found the correlation between the plasma level of CTX Ⅱ and the progression of the disease. |
Abstract |
Aim |
The aim of this study is to investigate the potential role of C-terminal cross-linking telopeptide of type II collagen (CTX-II) in the development of femoral head osteonecrosis (FHN).Materials and methodsOne hundred and thirty-two patients diagnosed with FHN and 66 age- and sex-matched healthy subjects were included in this cross-sectional case-control study between May 2016 and November 2016. Bone histomorphology, cartilaginous immunohistochemistry, Western blotting, and level of plasma CTX-II, as well as the receiver operating characteristic (ROC) curve, were evaluated. ResultsImmunohistochemistry and Western blotting showed that CTX-II was abundantly detected in the cartilage of FHN samples in stages III & IV. Plasma CTX-II levels were significantly higher in FHN patients in the advanced stages (III & IV) than was the level in the control group (164.81% and 198.15% higher in stages III & IV, respectively). However, the levels of CTX-II did not differ significantly among the FHN patients with different etiology or other clinical data. ConclusionOur result suggests that the degeneration of cartilage has already begun in stage III, even though a relatively normal articular gap can be found in the X-ray. Plasma CTX-II level may be a biomarker of the development of FHN.
Le texte complet de cet article est disponible en PDF.Keywords : C-terminal cross-linking telopeptide of type II collagen, Biomarkers, Femoral head osteonecrosis, Collapse
Plan
Vol 111
P. 1213-1220 - mars 2019 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?